This is one of a series of BMJ summaries of new guidelines based on the best available evidence; they highlight important recommendations for clinical practice, especially where uncertainty or controversy exists.
Stable angina is common. In England about 8% of men and 3% of women aged 55-64 years and about 14% of men and 8% of women aged 65-74 years have or have had angina.
1 Stable angina is associated with a low but appreciable risk of acute coronary events and increased mortality. However, evidence exists of inconsistencies in management. 2 This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of stable angina. 3 The diagnosis of stable angina is considered in an earlier NICE guideline. 4 
Recommendations
NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
Information and support for people with stable angina
• Explain stable angina and its long term course and management. Inform about factors that can provoke angina-for example, exertion, emotional stress, exposure to cold, or eating a heavy meal.
[Based on low to high quality evidence from qualitative studies and on the experience and opinion of the Guideline Development Group (GDG)]
• Explore and correct any misconceptions about stable angina and its implications for daily activities, heart attack risk, and life expectancy. Individual patients may benefit from discussion about: -Self management skills such as pacing their activities and goal setting -Concerns about the impact of stress, anxiety, or depression on angina -Advice about physical exertion including sexual activity.
[Based on low to high quality evidence from qualitative studies and experience and opinion of the GDG]
• A useful source of information for patients is the British Heart Foundation (www.bhf.org.uk/heart-health/conditions/ angina.aspx).
• • Tell people that when treating an episode of angina, they should: -Repeat the dose after five minutes if the pain has not gone -Call an emergency ambulance if the pain has not gone five minutes after taking a second dose.
• Advise the person with stable angina to seek professional help if they have a sudden worsening in the frequency or severity of their angina.
[ • For people taking either a β blocker alone or a calcium channel blocker alone whose symptoms are not controlled and the other option is contraindicated or not tolerated, consider one of the following as an additional drug: -A long acting nitrate or -Ivabradine, a selective inhibitor of pacemaker activity in the sinus node, or -Nicorandil, a vasodilator, or -Ranolazine, which acts on intracellular sodium currents to reduce myocardial ischaemia.
[Based on low to high quality evidence from randomised controlled trials and on the experience and opinion of the GDG]
• When combining a calcium channel blocker with either a β blocker or ivabradine, select a dihydropyridine calcium channel blocker-for example, slow release nifedipine, amlodipine or felodipine.
• 
• Do not offer a third anti-angina drug to people whose stable angina is controlled with two anti-angina drugs. Add a third anti-angina drug only when: -The person's symptoms are not controlled satisfactorily with two anti-angina drugs and -The person is waiting for revascularisation, or revascularisation is not considered appropriate or acceptable.
Overcoming barriers
Implementing this guideline will require physicians to modify attitudes in favour of optimal medical management as the initial, sometimes the only, treatment strategy for patients with angina. Cardiologists, cardiac surgeons, and other healthcare professionals need to determine in multidisciplinary team discussions the most appropriate revascularisation strategies for patients. Cardiologists and cardiac surgeons will also need to respond to the changing evidence base underpinning choice of revascularisation strategy (particularly for patients with left main and three vessel coronary artery disease) and recognise that the evidence for revascularisation on prognostic grounds is based on old trials conducted before the introduction of secondary prevention treatments that also improve prognosis. NO'F wrote the first draft, and all authors were involved in further drafting and reviewed and approved the final version for publication. NO'F is the guarantor.
Funding: The National Clinical Guideline Centre was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary.
Further information on the guidance
Substantial evidence exists of inconsistent practice relating to:
• The use of optimal medical treatment in patients referred for revascularisation 4 7 • Explanation to patients of benefits of revascularisation in terms of symptom relief and prognosis 8
• Discussion of revascularisation strategy in a multidisciplinary team 9
• Choice of revascularisation strategy.
10
What's new
• Requirement for optimal medical treatment before consideration of revascularisation
• Recognition that patients who respond to optimal medical treatment with relief of angina may need no further treatment
• Recognition that, in patients for whom both percutaneous and surgical revascularisation is feasible, percutaneous revascularisation is a more cost effective approach
Discussions with patients whose symptoms are controlled by drugs
The following information may help healthcare professionals when discussing investigation with patients whose symptoms are controlled by medical treatment.
Patients with stable angina are generally thought to have a good prognosis, although published information is limited.
11
In a large randomised trial, annual all cause mortality was 1.5%. 12 Studies in primary care have reported higher annual mortality rates, ranging from 2.8% to 6.6%. 13 The composite risk of a complication during coronary angiography is 1-2%, with a composite risk of death, myocardial infarction, or stroke of 0.1-0.2%. 14 15 The prevalence of left main stem disease in patients with stable angina whose symptoms are controlled by medical treatment is unknown. The Coronary Artery Surgery Study registry reported in 1989 that of 20 137 patients who had coronary angiography, left main coronary disease (≥50% stenosis) was found in 1477 patients (7.3%), but only 53 (3.6%) of these patients were asymptomatic. 16 In a 2006 registry report of 13 228 patients having coronary angiography, left main stem disease (≥60% stenosis) was found in 3.6%. 17 In 2008 a report based on a national adult cardiac surgical database stated that isolated, first time elective CABG surgery was associated with an in-hospital mortality of 1%, and rates of repeat surgery for bleeding, new renal support (haemofiltration or dialysis), and postoperative stroke were 2.9%, 1.8%, and 0.9% respectively. 18 Operative mortality increased with age (2.5% in those aged >75 years) and was higher in women and in patients with left main stem disease. 18 
Methods
The Guideline Development Group followed standard NICE methods in the development of this guideline (www.nice.org. uk/aboutnice/howwework/developingniceclinicalguidelines/developing_nice_clinical_guidelines.jsp). The group developed clinical questions; collected and appraised clinical evidence; and evaluated the cost effectiveness of proposed interventions through literature review and original economic modelling. The draft guideline went through a rigorous reviewing process, in which stakeholder organisations were invited to comment; all comments were considered when producing the final version of the guideline.
The guideline group comprised a chairperson (who is a cardiologist), two patient members, one radiologist, one pharmacist, one cardiac surgeon, two general practitioners, two nurses, and three other cardiologists.
Future research
The guideline group identified the following areas as needing further research.
What is the long term value of adding newer anti-angina drugs to a calcium channel blocker?
Does routine angiography with a view to revascularisation improve outcomes in people with stable angina who are receiving optimal medical treatment and have evidence of ischaemia?
Do early investigation and revascularisation improve longer term survival in what is considered "high risk" anatomy, such as left main stem disease, in people whose symptoms are controlled with medical treatment?
What is the long term value of cardiac rehabilitation for patients with stable angina?
What is the value of self management plans for patients with stable angina?
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